Jonathan P Piccini

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Use of cardiac resynchronization therapy in patients hospitalized with heart failure
    Jonathan P Piccini
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Circulation 118:926-33. 2008
  2. doi request reprint Optimal timing of implantable cardioverter-defibrillator implantation after myocardial infarction: a decision analysis
    Jonathan P Piccini
    Duke Clinical Research Institute and the Duke University School of Medicine, Durham, North Carolina 27705, USA
    J Cardiovasc Electrophysiol 21:791-8. 2010
  3. doi request reprint Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 61:1998-2006. 2013
  4. doi request reprint Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K ant
    Jonathan P Piccini
    Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27710, USA
    Circulation 127:224-32. 2013
  5. doi request reprint Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes
    Jonathan P Piccini
    Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27705, USA
    Circulation 126:41-9. 2012
  6. doi request reprint Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial
    Jonathan P Piccini
    Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Eur Heart J 31:211-21. 2010
  7. doi request reprint Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Curr Opin Cardiol 25:312-20. 2010
  8. doi request reprint Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
    Jonathan P Piccini
    Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Heart Rhythm 8:393-400. 2011
  9. doi request reprint Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation
    Jonathan P Piccini
    Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 54:1089-95. 2009
  10. doi request reprint Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF
    Jonathan P Piccini
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 162:606-612.e1. 2011

Collaborators

Detail Information

Publications65

  1. doi request reprint Use of cardiac resynchronization therapy in patients hospitalized with heart failure
    Jonathan P Piccini
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Circulation 118:926-33. 2008
    ....
  2. doi request reprint Optimal timing of implantable cardioverter-defibrillator implantation after myocardial infarction: a decision analysis
    Jonathan P Piccini
    Duke Clinical Research Institute and the Duke University School of Medicine, Durham, North Carolina 27705, USA
    J Cardiovasc Electrophysiol 21:791-8. 2010
    ..The optimal timing of implantable cardioverter defibrillator (ICD) placement for the primary prevention of sudden cardiac death after myocardial infarction (MI) remains unknown...
  3. doi request reprint Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 61:1998-2006. 2013
    ..This study sought to investigate the outcomes following cardioversion or catheter ablation in patients with atrial fibrillation (AF) treated with warfarin or rivaroxaban...
  4. doi request reprint Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K ant
    Jonathan P Piccini
    Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27710, USA
    Circulation 127:224-32. 2013
    ..We sought to define the factors associated with the occurrence of stroke and systemic embolism in a large, international atrial fibrillation (AF) trial...
  5. doi request reprint Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes
    Jonathan P Piccini
    Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27705, USA
    Circulation 126:41-9. 2012
    ..However, the incidence and prognosis of sustained ventricular tachycardia/ventricular fibrillation (VT/VF) in contemporary non-ST-segment-elevation (NSTE) ACS populations are not well described...
  6. doi request reprint Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial
    Jonathan P Piccini
    Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Eur Heart J 31:211-21. 2010
    ..To determine whether predictors of sudden cardiac death (SCD) vary with time after myocardial infarction (MI)...
  7. doi request reprint Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Curr Opin Cardiol 25:312-20. 2010
    ..Consequently, much research has been focused on finding an alternative to warfarin. We review the potential alternatives in development and evaluate the current evidence concerning their safety and efficacy...
  8. doi request reprint Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
    Jonathan P Piccini
    Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Heart Rhythm 8:393-400. 2011
    ....
  9. doi request reprint Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation
    Jonathan P Piccini
    Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 54:1089-95. 2009
    ..We sought to compare the efficacy and safety of dronedarone versus amiodarone for the prevention of recurrent atrial fibrillation (AF)...
  10. doi request reprint Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF
    Jonathan P Piccini
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 162:606-612.e1. 2011
    ..Data on contemporary treatment patterns and outcomes associated with AF in clinical practice are limited...
  11. pmc Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Crit Care Med 39:78-83. 2011
    ..The objective of this analysis was to describe the survival of patients with sustained ventricular tachycardia/ventricular fibrillation after myocardial infarction according to antiarrhythmic drug treatment...
  12. doi request reprint Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials
    Jonathan P Piccini
    Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center 31115, Durham, NC 27710, USA
    Eur Heart J 30:1245-53. 2009
    ..There are conflicting data regarding the efficacy and safety of amiodarone for the prevention of SCD...
  13. doi request reprint Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Re
    Jonathan P Piccini
    Division of Cardiology, Department of Medicine, and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am J Cardiol 102:1427-32. 2008
    ..Unfortunately, beta blockers were underused acutely in patients with sustained VT/VF...
  14. ncbi request reprint Rivaroxaban, an oral direct factor Xa inhibitor
    Jonathan P Piccini
    Duke University Medical Center, Duke Clinical Research Institute, 2400 Pratt Street, 7581, Durham, NC 27705, USA
    Expert Opin Investig Drugs 17:925-37. 2008
    ..The drug may have its greatest impact in providing a much-needed and attractive alternative to warfarin. Further data (especially large Phase III trials) are required...
  15. doi request reprint Early sustained ventricular arrhythmias complicating acute myocardial infarction
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am J Med 121:797-804. 2008
    ..The objective of this analysis was to identify predictors of sustained ventricular arrhythmias after acute MI and to determine the influence of successful revascularization on in-hospital mortality...
  16. pmc Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial
    Daniel E Singer
    Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Am Heart Assoc 2:e000067. 2013
    ..Time in therapeutic range (TTR) is a widely cited measure of the quality of VKA therapy. We sought to identify factors associated with TTR in a large, international clinical trial...
  17. doi request reprint Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry
    Benjamin A Steinberg
    MPH, Duke University Medical Center and Duke Clinical Research Institute, 2400 Pratt St, Ste 7009, Durham, NC 27705, USA
    Circulation 128:721-8. 2013
    ..We assessed concomitant ASA use and its association with clinical outcomes among AF patients treated with OAC...
  18. doi request reprint Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Ann Intern Med 158:861-8. 2013
    ....
  19. pmc Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation
    Jonathan P Piccini
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    Circulation 126:2200-7. 2012
    ..Atrial fibrillation is common among older persons. Catheter ablation is increasingly used in patients for whom medical therapy has failed...
  20. doi request reprint Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention o
    Manesh R Patel
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 61:651-8. 2013
    ..The purpose of this study was to understand the possible risk of discontinuation in the context of clinical care...
  21. pmc Atrial fibrillation among Medicare beneficiaries hospitalized with sepsis: incidence and risk factors
    Allan J Walkey
    Pulmonary Center and the Section of Pulmonary and Critical Care Medicine, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
    Am Heart J 165:949-955.e3. 2013
    ..However, the prevalence, incidence, and risk factors associated with AF during the sepsis syndromes are unclear...
  22. doi request reprint Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    Manesh R Patel
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    N Engl J Med 365:883-91. 2011
    ..Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin...
  23. pmc Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients
    Connie N Hess
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 164:607-15. 2012
    ..Balancing safe and effective use of aspirin, clopidogrel, and warfarin in this population is important...
  24. pmc Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure
    Kevin L Thomas
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC
    J Am Heart Assoc 2:e000200. 2013
    ..We sought to determine the prevalence of AF, characteristics, in-hospital outcomes, and warfarin use associated with AF in patients hospitalized with HF as a function of race...
  25. pmc International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation
    Jorge Suarez
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am Heart J 163:804-11. 2012
    ..We sought to characterize patient factors and regional variations associated with vitamin K antagonist (VKA) use in patients with heart failure (HF) and atrial fibrillation (AF) in areas outside the United States and Europe...
  26. doi request reprint Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation
    Paul L Hess
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am J Med 126:625-32.e1. 2013
    ..Patients with atrial fibrillation often have cardiovascular risk factors or known comorbid disease, yet the use of evidence-based primary and secondary prevention cardiac therapy among atrial fibrillation outpatients is unknown...
  27. doi request reprint Predictors of mortality in patients with chronic kidney disease and an implantable defibrillator: an EPGEN substudy
    Eric S Williams
    Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA
    Europace 13:1717-22. 2011
    ..Clinical trials of the implantable cardioverter-defibrillator (ICD) have demonstrated a survival benefit over medical therapy for the prevention of sudden cardiac death, but its benefit in patients with concomitant CKD is unclear...
  28. doi request reprint Quality of care for atrial fibrillation among patients hospitalized for heart failure
    Jonathan P Piccini
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 54:1280-9. 2009
    ..This study sought to examine quality of care and warfarin use at discharge in patients with atrial fibrillation (AF) and heart failure (HF)...
  29. doi request reprint QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy
    Pamela N Peterson
    Division of Cardiology, Department of Medicine, Denver Health Medical Center, Denver, CO 80204, USA
    JAMA 310:617-26. 2013
    ..The benefits of cardiac resynchronization therapy (CRT) in clinical trials were greater among patients with left bundle-branch block (LBBB) or longer QRS duration...
  30. doi request reprint Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
    Benjamin A Steinberg
    Duke University Medical Center, Durham, NC 27715, USA
    Am Heart J 165:622-9. 2013
    ..All patients with atrial fibrillation (AF) require optimization of their ventricular rate. Factors leading to use of additional rhythm control in clinical practice have not been thoroughly defined...
  31. doi request reprint Comparative effectiveness of pharmacotherapies for prevention of atrial fibrillation following coronary artery bypass surgery
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina Electronic address
    Am J Cardiol 112:954-60. 2013
    ..In this high-risk population, we were unable to demonstrate that any of the commonly used preventive agents were associated with lower rates of AF compared with alternatives or no treatment. ..
  32. doi request reprint Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials
    Jonathan P Piccini
    Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Circ Arrhythm Electrophysiol 2:626-33. 2009
    ..The efficacy and safety of pulmonary vein isolation (PVI) compared with medical therapy remain in question...
  33. doi request reprint Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction
    Emil L Fosbol
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 163:720-8. 2012
    ..We aimed to study the comparative safety and effectiveness of various antithrombotic treatment strategies among older adults with non-ST elevation myocardial infarction (NSTEMI) and atrial fibrillation (AF)...
  34. doi request reprint Single-photon emission computed tomography myocardial perfusion imaging and the risk of sudden cardiac death in patients with coronary disease and left ventricular ejection fraction>35%
    Jonathan P Piccini
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 56:206-14. 2010
    ....
  35. doi request reprint Management of Postoperative Atrial Fibrillation and Subsequent Outcomes in Contemporary Patients Undergoing Cardiac Surgery: Insights From the Society of Thoracic Surgeons CAPS-Care Atrial Fibrillation Registry
    Benjamin A Steinberg
    Department of Medicine, Duke University Medical Center, Durham, North Carolina Duke Clinical Research Institute, Durham, North Carolina
    Clin Cardiol 37:7-13. 2014
    ..Postoperative atrial fibrillation (POAF) is a well-recognized complication of cardiac surgery; however, its management remains a challenge, and the implementation and outcomes of various strategies in clinical practice remain unclear...
  36. doi request reprint Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial
    Kenneth W Mahaffey
    Department of Medicine, Stanford University, Stanford, CA, USA
    Eur Heart J 35:233-41. 2014
    ..We investigated the prevalence of prior myocardial infarction (MI) and incidence of ischaemic cardiovascular (CV) events among atrial fibrillation (AF) patients...
  37. pmc Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation
    Benjamin A Steinberg
    Duke University Medical Center, Durham, NC
    J Am Heart Assoc 2:e000535. 2013
    ..Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown...
  38. pmc Pharmacotherapy in Medicare beneficiaries with atrial fibrillation
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA
    Heart Rhythm 9:1403-8. 2012
    ..There are limited data regarding national patterns of pharmacotherapy for atrial fibrillation (AF) among older patients. Drug exposure data are now captured for Medicare beneficiaries enrolled in prescription drug plans...
  39. doi request reprint Relationship of sustained ventricular tachyarrhythmias to outcomes in patients undergoing primary percutaneous coronary intervention with varying underlying baseline risk
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 161:782-9. 2011
    ....
  40. doi request reprint Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA
    Eur Heart J 35:250-6. 2014
    ..However, the relative event rates for these outcomes are not well described. We sought to define the risks of major clinical events in older adults after a new diagnosis of atrial fibrillation...
  41. doi request reprint Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF
    William Schuyler Jones
    Duke Clinical Research Institute, Duke University Medical Center, Box 3126, Durham, NC, USA
    Eur Heart J 35:242-9. 2014
    ....
  42. doi request reprint Impact of using a telescoping-support catheter system for left ventricular lead placement on implant success and procedure time of cardiac resynchronization therapy
    Kevin P Jackson
    Division of Clinical Cardiac Electrophysiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Pacing Clin Electrophysiol 36:553-8. 2013
    ..We sought to evaluate the impact of an LV lead implant approach using telescoping-support catheters (group TS) on success rate, lead location, and procedural time compared to standard over-the-wire implant techniques (group OTW)...
  43. pmc Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies
    Benjamin A Steinberg
    Duke Center for Atrial Fibrillation, Electrophysiology Section, Duke University Medical Center, Durham, NC, USA
    J Interv Card Electrophysiol 37:213-21. 2013
    ..Dabigatran is approved for prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF). The safety and effectiveness of periprocedural dabigatran in ablation for AF are unknown...
  44. doi request reprint Surgical Maze procedure as a treatment for atrial fibrillation: a meta-analysis of randomized controlled trials
    Melissa H Kong
    Duke University Medical Center, Durham, NC 27710, USA
    Cardiovasc Ther 28:311-26. 2010
    ..Large RCTs defining rates of freedom from AF without AADs postprocedure, are still needed to evaluate outcomes and determine the appropriate role for surgical Maze procedures in the management of AF...
  45. doi request reprint End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Circ Cardiovasc Qual Outcomes 6:470-8. 2013
    ..To evaluate the previously reported excess of thromboembolic events during the 30 days after the end of study (EOS) visit when participants transitioned from blinded therapy to open-label vitamin K antagonist...
  46. pmc Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry
    Emil L Fosbol
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    J Am Heart Assoc 2:e000110. 2013
    ..The prevalence of atrial fibrillation (AF) continues to increase; however, there are limited data describing the division of care among practitioners in the community and whether care differs depending on provider specialty...
  47. doi request reprint Cardiac conduction system disease after transcatheter aortic valve replacement
    Benjamin A Steinberg
    Division of Cardiology, Department of Medicine, DukeUniversity Hospital, Durham, NC 27705, USA
    Am Heart J 164:664-71. 2012
    ....
  48. doi request reprint Extent of and reasons for nonuse of implantable cardioverter defibrillator devices in clinical practice among eligible patients with left ventricular systolic dysfunction
    Nancy M Allen LaPointe
    Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27705, USA
    Circ Cardiovasc Qual Outcomes 4:146-51. 2011
    ..The extent and documented reasons for nonuse of ICDs among patients with left ventricular systolic dysfunction are unknown...
  49. doi request reprint Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Thromb Thrombolysis 26:167-74. 2008
    ....
  50. doi request reprint Single-photon emission computed tomography myocardial perfusion defects are associated with an increased risk of all-cause death, cardiovascular death, and sudden cardiac death
    Jonathan P Piccini
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Circ Cardiovasc Imaging 1:180-8. 2008
    ..However, it is unknown whether single-photon emission computed tomography myocardial perfusion imaging can identify patients at increased risk of sudden cardiac death (SCD)...
  51. pmc Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    Circ Cardiovasc Qual Outcomes 5:85-93. 2012
    ..The frequency of AF increases with age, but representative national data about incidence and prevalence are limited. We examined the annual incidence, prevalence, and mortality associated with AF among older persons...
  52. doi request reprint Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial)
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 109:805-12. 2012
    ..Further studies are required to address the prognostic significance of VT/VF in patients with STEMI undergoing PPCI...
  53. doi request reprint Use of ventricular synchronized triggered atrial pacing to facilitate hemodynamic support during mapping and catheter ablation of ventricular vachycardia
    Jonathan P Piccini
    Cardiac Electrophysiology Section, Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA
    J Cardiovasc Electrophysiol 22:1174-8. 2011
    ..Thus, VSTAP is a readily available and noninvasive technique that may provide adequate hemodynamic support during catheter ablation of unstable VT...
  54. pmc Efficacy of adjunctive ablation of complex fractionated atrial electrograms and pulmonary vein isolation for the treatment of atrial fibrillation: a meta-analysis of randomized controlled trials
    Melissa H Kong
    Duke University Medical Center, Clinical Cardiac Electrophysiology Section of the Division of Cardiovascular Diseases, DUMC Box 31294, Durham, NC 27710, USA
    Europace 13:193-204. 2011
    ..The ablation of complex fractionated atrial electrograms (CFAEs) has been proposed as an adjunctive strategy to improve the maintenance of sinus rhythm after PVI. Our objective was to analyse the efficacy of adjunctive CFAE ablation...
  55. doi request reprint Mode of induction of ventricular tachycardia and prognosis in patients with coronary disease: the Multicenter UnSustained Tachycardia Trial (MUSTT)
    Jonathan P Piccini
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Cardiovasc Electrophysiol 20:850-5. 2009
    ..However, it is unknown whether the mode of VT induction is associated with long-term prognosis...
  56. doi request reprint Remote monitoring of implantable cardioverter defibrillators versus quarterly device interrogations in clinic: results from a randomized pilot clinical trial
    Sana M Al-Khatib
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Cardiovasc Electrophysiol 21:545-50. 2010
    ..We sought to determine whether remote monitoring of ICDs improves patient outcomes compared with quarterly device interrogations in clinic...
  57. pmc Retrograde ascending aortic dissection as an early complication of thoracic endovascular aortic repair
    Judson B Williams
    Division of Thoracic and Cardiovascular Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Vasc Surg 55:1255-62. 2012
    ..This study examines the incidence, etiology, and outcome of this event...
  58. pmc The S1103Y cardiac sodium channel variant is associated with implantable cardioverter-defibrillator events in blacks with heart failure and reduced ejection fraction
    Albert Y Sun
    Division of Cardiovascular Diseases, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Circ Cardiovasc Genet 4:163-8. 2011
    ..We hypothesized that the S1103Y cardiac sodium channel SCN5A variant influences the propensity for ventricular arrhythmias in black patients with heart failure and reduced ejection fraction...
  59. doi request reprint Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials
    Paul L Hess
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Heart Rhythm 10:828-35. 2013
    ..Whether there is an optimal time to place an implantable cardioverter-defibrillator (ICD) more than 40 days after myocardial infarction (MI) in guideline-eligible patients is unknown...
  60. doi request reprint Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative
    Jonathan P Piccini
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 158:317-26. 2009
    ..Priority pursuit of these consensus-based directions should facilitate both safer drugs and accelerated access to new drugs, as concomitant public health benefits...
  61. doi request reprint Cryoablation of atrial fibrillation
    Jonathan P Piccini
    Duke Center for Atrial Fibrillation Cardiac Electrophysiology Section, Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA
    J Interv Card Electrophysiol 32:233-42. 2011
    ....
  62. ncbi request reprint Predictors of appropriate implantable defibrillator therapies in patients with arrhythmogenic right ventricular dysplasia
    Jonathan P Piccini
    Division of Cardiology, Department of Medicine, The Johns Hopkins Hospital, 600 N Wolfe Street, Carnegie 592, Baltimore, MD 21287, USA
    Heart Rhythm 2:1188-94. 2005
    ..The risk factors for sudden death and indications for implantable cardioverter-defibrillator (ICD) placement in patients with ARVD are not well defined...
  63. doi request reprint Device therapy in heart failure patients with chronic kidney disease
    Leon A Cannizzaro
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 58:889-96. 2011
    ..Given this lack of clear evidence, pragmatic clinical trials and comparative effectiveness studies are needed to help identify the appropriate use of ICD and CRT devices in this high-risk population of patients with HF and CKD...
  64. doi request reprint Rationale and design of the Duke Electrophysiology Genetic and Genomic Studies (EPGEN) biorepository
    Jason I Koontz
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 158:719-25. 2009
    ..Many arrhythmias are known to have a heritable component, but the degree to which genetic variation contributes to disease risk and morbidity is poorly understood...
  65. ncbi request reprint Electrocardiographic findings over time in arrhythmogenic right ventricular dysplasia/cardiomyopathy
    Jonathan P Piccini
    Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Am J Cardiol 96:122-6. 2005
    ..Over a median of 43 months, 89% of the patients had evidence of progression, with S-wave prolongation being the most prevalent marker of ECG progression...